Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer
The trial will evaluate the optimal treatment with nab-paclitaxel in combination with either carboplatin or gemcitabine for patients with triple negative breast cancer.
- Trial name
- ADAPT (NCT01815242)
- Testing
- nab-Paclitaxel, Gemcitabine, Carboplatin
- Where
- Germany
- Volunteers
- 336 people
- Sponsor
- Women's Cancer Study Group GmbH
Breast Neoplasms
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2…
- Trial name
- EMBER-4 (NCT05514054)
- Testing
- Imlunestrant, Tamoxifen, Anastrozole
- Where
- 672 sites in United States, Argentina and 29 more
- Volunteers
- 8,000 people
- Sponsor
- Eli Lilly and Company
Early Stage Breast Cancer
A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer
This study is designed to randomly assign breast cancer patients requiring and agreeing to chemotherapy into two groups. One group will be receive an exercise prescription aimed at increasing physical activity by a minimum of 10…
- Trial name
- NCT02159157
- Testing
- Exercise prescription
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)
Praegnant Breast Cancer: Early/Advanced/Metastatic
Among patients with breast cancer the subgroup of patients with metastases are considered the group of patients with the worst prognosis.
- Trial name
- PRAEGNANT (NCT02338167)
- Testing
- Blood sampling
- Where
- 61 sites in Germany
- Volunteers
- 13,500 people
- Sponsor
- University Hospital Tuebingen
Early Breast Cancer
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
A phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with Endocrine Therapy (ET) as an adjuvant treatment in women and men with Hormone Receptor positive (HR+), Human Epidermal…
- Trial name
- NATALEE (NCT03701334)
- Testing
- Ribociclib, Endocrine Therapy (ET)
- Where
- 387 sites in United States, Argentina and 18 more
- Volunteers
- 5,101 people
- Sponsor
- Novartis Pharmaceuticals
HER2-positive Breast Cancer
Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study
Neratinib is an oral, irreversible pan-HER tyrosine kinase inhibitor. Current treatment guidelines recommend neratinib as an extended adjuvant therapy for HER2-positive breast cancer patients to further reduce the risk of…
- Trial name
- NCT07019272
- Testing
- Neratinib (HKI-272)
- Volunteers
- 170 people
- Sponsor
- Hebei Medical University Fourth Hospital
Invasive Breast Cancer, Ductal Carcinoma in Situ
Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer
The primary objective of this study is to identify the group of women with early stage breast cancer most likely to benefit from treatment with the selective progesterone receptor modulator (SPRM) mifepristone.
- Trial name
- NCT01138553
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Diego
Breast Cancer, Radiotherapy Side Effect
Super-Hypofractionated Partial Breast Irradiation
Partial breast irradiation is currently a hot topic in clinical research, but the appropriate population and appropriate irradiation The technology and dose fractionation mode are still inconclusive.
- Trial name
- NCT06615466
- Testing
- Partial Breast Irradiation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer
The purpose of this clinical trial is to evaluate the efficacy and safety of Utidelone plus AC versus Docetaxel plus AC as neoadjuvant chemotherapy in high-risk HER2-negative early-stage or locally advanced breast cancer.
- Trial name
- NCT05673629
- Testing
- Utidelone Injection in combination with AC, Docetaxel Injection in combination with AC
- Where
- China
- Volunteers
- 552 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Female Breast Cancer
PrefeRences And ChemoTherapy In Breast Cancer patiEnts
The aim of the present study is to ask women treated with adjuvant or neoadjuvant chemotherapy for breast cancer what survival benefit would justify the treatment.
- Trial name
- PRACTICE (NCT06332976)
- Testing
- Completion of questionnaires
- Where
- Italy
- Volunteers
- 450 people
- Sponsor
- European Institute of Oncology
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
This 3 arm study will assess the tolerability, safety and efficacy of 3 neoadjuvant treatment regimens in participants with locally advanced, inflammatory or early stage human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00976989
- Testing
- Pertuzumab, Trastuzumab, FEC
- Where
- 55 sites in Bosnia and Herzegovina, Brazil and 18 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms, Early Detection of Cancer
Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
The primary purpose of this study is to determine the impact of maximizing patient and primary care provider (PCP) activation on breast cancer surveillance rates among women previously treated with chest radiotherapy (RT) for a…
- Trial name
- NCT03435380
- Testing
- Patient activation, Primary care physician activation, Control
- Where
- 5 sites in United States
- Volunteers
- 314 people
- Sponsor
- Duke University
Metastatic Non-Small Cell Lung Carcinoma, Metastatic Colorectal Cancer
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer
Accrue samples for the further development and clinical validation of a blood-based cell-free DNA (cfDNA) quantitative real-time polymerase chain reaction (qPCR) assay as a potential biomarker for early non-response to therapy in…
- Conditions
- Metastatic Non-Small Cell Lung Carcinoma, Metastatic Colorectal Cancer, Metastatic Breast Cancer
- Trial name
- NCT03892096
- Testing
- Blood-based cell-free cfDNA qPCR assay
- Where
- 12 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Cadex Genomics
HER2 + Breast Cancer
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
The study is being conducted to evaluate the clinical efficacy of HLX87 in combination with HLX22 or pertuzumab vs. TCbHP in the neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.
- Trial name
- NCT07294534
- Testing
- HLX87+HX22, HLX87 + Pertuzumab, TCbHP
- Volunteers
- 817 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Matrix Rotation Flap Versus Single Incision Lateral Sulcus Mammoplasty
The study seeks to compare the single-incision lateral mammoplasty technique with the matrix rotation flap in patients with breast carcinoma.
- Trial name
- SLIM (NCT07022509)
- Testing
- proceduder surgery, Technique surgery
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Batterjee Medical College
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Reflects the Intervention (AI Chatbot)
The goal of this clinical trial is to investigate the impact of an AI-powered chatbot intervention on improving knowledge, attitudes, and empowerment in breast cancer patients.
- Trial name
- BC-CHAT (NCT06943911)
- Testing
- AI Chatbot for Breast Cancer Patient Education and Empowerment
- Where
- Egypt
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Mostafa Shaban
Breast Diseases, Breast Neoplasms
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
This study is a multicenter, prospective, randomized, open-label clinical study to assess the efficacy and safety of endocrine combined with different doses and treatment duration of darisenatide adjuvant therapy in HR +/HER2…
- Conditions
- Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases
- Trial name
- NCT07581834
- Testing
- Dalpiciclib 125mg, Dalpiciclib 100mg, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
- Where
- 2 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Fujian Cancer Hospital
Prostate Cancers, Breast Cancer
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II.
- Conditions
- Prostate Cancers, Breast Cancer, Lung Cancers, Ovarian Cancer
- Trial name
- ADVICE (NCT06926075)
- Testing
- A novel hGIIA-Vimentin Inhibitor, Dose expansion
- Where
- 3 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Filamon LTD
HER2-positive Breast Cancer
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed…
- Trial name
- NCT04481932
- Testing
- Trastuzumab combined with Pyrotinib and chemotherapy
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Peking University
Triple Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast…
- Trial name
- NCT05112536
- Testing
- Trilaciclib, Cylophosphamide, Doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- G1 Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.